Deal Making Just Got Tougher for Struggling Generic Drugmakers


William Diaz and Jonathan Ende were authors of a blog post cited here, “Divestitures of Complex Pipeline Pharmaceutical Products off the Table at the FTC,” in which they analyzed an internal FTC study which revealed that the failure rate was high for divestitures of certain complex pharmaceutical products under development.